Venture Capital Access Online | The eMarketplace for the Venture Capital Industry


Bookmark and Share   


Contact Us





VCPro Database 2014 (17th Edition) Now Available! Newly released

Venture Capital Deals Spreadsheet Now Available Newly released


DioGenix Raises $3.2 Million for Novel Molecular Diagnostic for Multiple Sclerosis, MSPrecise

GAITHERSBURG, Md., December 5, 2013-- DioGenix, Inc. announced today that it raised $3.2 million in a private financing consisting of new individual investors and returning investors including life sciences fund Nerveda, LLC. The financing follows recent interim results from a prospective clinical trial of DioGenix' MSPrecise®, a next-generation sequencing assay, which continues to show that it can accurately identify patients with multiple sclerosis (MS) at first clinical presentation.

The financing will support the completion of the largest prospective clinical diagnostic trial of its kind in MS. This study should validate the performance of MSPrecise in a population of patients being evaluated for MS and a variety of other neurological diseases. DioGenix has also established a new central laboratory that will serve as the basis for the company's future commercialization of MSPrecise upon CLIA licensure.

DioGenix also announced that it has expanded its licensing arrangement with the University of Texas Southwestern Medical Center (UTSW) to provide exclusivity to core technology related to MSPrecise for MS and other neurological diseases.

"DioGenix exemplifies an ideal investment for Nerveda, as MSPrecise could significantly improve upon existing methods for diagnosing multiple sclerosis and other neurological diseases. DioGenix has achieved important development and business milestones that pave the way for its lead product to achieve additional clinical progress in 2014," said Cam Gallagher, Chairman of DioGenix and President of Nerveda, a private life science fund.

"Our new and long-term investors appreciate the value proposition of MSPrecise – to give physicians superior tools and insights when they are evaluating patients with neurological dysfunction at first clinical presentation. With the growing portfolio of therapeutics now available for MS, it is critical that we achieve similar innovations in our diagnostic methods to ensure patients obtain early and appropriate interventions," said Larry Tiffany, President and CEO of DioGenix.

Patients that present with clinical symptoms and evidence of non-specific neurological disease undergo a battery of tests in a diagnostic process that can take months or even years to complete. The diagnostic standard of care for MS includes cerebral spinal fluid analysis using the oligoclonal banding test alongside a comprehensive set of clinical tests to rule-out other neurological diseases. Unfortunately, the oligoclonal banding test yields a high rate of false positive results, which can unnecessarily expose patients who do not have MS to chronic and expensive therapy that, in some cases, actually exacerbates their underlying disease. Alternatively, false negatives can delay the proper treatment of those patients who do have MS, possibly accelerating the development of permanent physical disability.

In previous studies, MSPrecise outperformed the specificity of the current standard of care for cerebral spinal fluid analysis in patients suspected of having MS by almost two to one with no loss of sensitivity. The current prospective, blinded, multi-site trial is designed to further validate DioGenix' deep-sequencing approach.

About MSPrecise®

MSPrecise utilizes next-generation sequencing to measure DNA mutations found in rearranged immunoglobulin genes in immune cells initially isolated from cerebrospinal fluid. MSPrecise would augment the current standard of care for the diagnosis of MS by providing a more accurate measurement of a patient's immune response to a challenge within the central nervous system. This novel method of measuring changes in adaptive human immunity may also be able to discern individuals whose disease is more progressive and requires more aggressive treatment.

About DioGenix, Inc.

DioGenix is developing novel molecular tests using application-specific, high-resolution state-of-the-art technologies that measure well-established human biology. With a focus in immune-mediated neurological diseases and disorders, DioGenix combines powerful insight into clinical diagnostic pathways with proprietary technology that results in earlier, more personalized intervention and treatment. The company's lead product, MSPrecise®, is currently being evaluated in a prospective trial to evaluate its clinical performance in identifying patients that have, or are at risk of developing multiple sclerosis. DioGenix is based Gaithersburg, MD. For additional information, please visit

Larry Tiffany
CEO, DioGenix
(301) 529-4943

Pam Lord
Canale Communications for DioGenix
(619) 849-6003

News Index

Venture Capital Database

Venture Capital Deals Spreadsheet



Latest VC News
VC News Archive
News Search
Venture Capital Deals New
RSS News Feed

List Your Firm


Venture Capital Database

VCPro Database
Download Trial
Buy Now

Venture Capital Deals

Download Sample
Buy Now

VC Tools

Venture Capital StarterPak
VC Pitch
Private Placement Memorandum
Confidentiality Agreement Package
Series A Preferred Term Sheet
Bridge Financing Contract
Employment Agreements
Understanding Employee Stock Options

Business Plan Tools

Free Business Plan Template
Sample Business Plans
Business Plan Pro



Copyright © 1998-2014 Access InterComm  All rights reserved. 
Site Map | Privacy Statement | Legal Notice & Disclaimer